Every trade and directional call the AI fund has made on JNJ, newest first, each linked to that day's full decision.
Negative five-day and 30-day trends suggest near-term relative weakness despite a gain versus cost.
Negative 5-day momentum and a slightly negative 30-day return suggest modest relative weakness despite gains from cost.
Slightly negative five-day and 30-day returns suggest modest underperformance versus SPY despite its defensive characteristics.
Positive five-day performance and defensive characteristics support modest relative resilience despite a slightly negative 30-day return.
Slightly positive 5-day and 30-day returns plus potential talc-resolution progress support a narrow edge over SPY.
JNJ's modest positive 30-day return and defensive characteristics provide a small relative edge in an uneven market.
Defensive healthcare exposure, favorable recent coverage, and a dividend profile support relative resilience during a rate-driven equity pullback.
Near-flat 30-day performance trails the benchmark and leaves limited evidence for near-term relative leadership despite positive absolute portfolio returns.
Positive short- and medium-term momentum plus talc-resolution optimism support a defensive relative advantage.
Positive 5-day and 30-day returns in a declining broad market support defensive relative strength versus SPY.
Positive 5-day and 30-day momentum, a 52-week-high reference and defensive characteristics support relative strength versus SPY.
Positive 30-day performance and flat five-day action demonstrate defensive relative resilience versus a declining SPY.
Positive 30-day performance in a weak market and potential talc-litigation uncertainty reduction support relative resilience.
JNJ's positive 1.9% 30-day return compares favorably with SPY's decline and provides a relatively defensive earnings profile.
Positive 30-day performance and a substantial gain versus cost support relative resilience, though the recent pullback limits conviction.
JNJ's positive 30-day return and defensive profile favor relative resilience despite its recent 4.1% pullback.
Positive 30-day relative strength and defensive health-care characteristics are favorable in a rate-and-oil shock.
Its 8.5% 30-day and 1.5% five-day gains make it a clear defensive momentum leader versus SPY.
Its strong 5-day and 30-day gains and defensive positioning support continued relative strength versus SPY.
Strong 3.88% five-day and 9.15% 30-day momentum supports defensive relative strength, though litigation uncertainty remains.
Strong five-day and 30-day gains provide defensive relative strength in an uneven market.
Its positive 30-day trend is modest, and its large existing allocation limits incremental appeal versus SPY.
JNJ's defensive quality and flat 30-day performance may compare favorably if yields, oil, and geopolitical risks pressure growth equities.
A 7.4% 30-day gain, positive short-term momentum and defensive healthcare characteristics support relative strength.
An 8.95% 30-day gain and positive five-day return materially exceed SPY, though the near-record level limits conviction.
JNJ's 8.6% 30-day gain and 3.0% five-day gain demonstrate sustained relative strength versus SPY.
JNJ is up 2.7% over five days and 5.7% over 30 days, demonstrating resilient relative strength.
Strong five-day and 30-day returns, plus defensive characteristics, support continued relative strength versus SPY.
Strong positive returns over five and 30 days demonstrate durable relative strength.
Positive momentum and a defensive profile support resilience, but its 3.4% 30-day return slightly trails SPY and valuation concerns remain.
Defensive quality and positive 30-day performance support stability, but modest momentum likely trails a constructive SPY environment.
Positive five-day and 30-day returns, alongside potential talc-litigation resolution, support modest relative strength.
Stable positive returns support holding, but its modest momentum is unlikely to exceed SPY materially.
JNJ's -1.37% 30-day return trails SPY, although its defensive characteristics and gain versus cost limit downside conviction.
JNJ's positive 5-day move is encouraging, but its negative 30-day return trails SPY and limits relative-return conviction.
Essentially flat 30-day performance trails SPY, even though the holding remains profitable and defensive.
Stable but near-zero momentum limits upside relative to SPY.
JNJ shows mixed momentum with positive fundamental developments; expect roughly in line with SP500.
Mixed news and slight positive returns keep the outlook neutral to slightly positive.
Johnson & Johnson's stable fundamentals but weak momentum indicate performance roughly in line with SPY.
Stable returns and positive recent news signal likely outperformance versus broader market.
Positive trial news and defensive healthcare exposure favor outperforming amid market volatility.
Positive momentum and undervaluation signals support modest outperformance versus SPY.
Strong legal resolution and positive earnings outlook support outperformance in healthcare.
Strong fundamentals and positive news flow in healthcare anticipate outperformance.
Solid fundamentals and moderate positive momentum support modest outperformance.
Stable dividend yield and positive fundamentals support outperformance versus SPY.
JNJ’s steady momentum and innovation outlook support outperformance potential.
Fair valuation and steady fundamentals support performance roughly in line with SPY.
Steady returns and mixed momentum justify neutral performance expectation.
Positive earnings guidance and dividend stability ought to support relative returns.
Modest positive momentum and defensive sector position support performance around market average.
Positive earnings guidance and defensive healthcare exposure bode well versus benchmark.
JNJ’s positive momentum and upcoming catalysts support outperformance.
Strong 30-day momentum and defensive characteristics support a positive performance vs SPY.
Steady momentum and defensive sector status support JNJ outperforming the market.
Strong recent gains and investor confidence position JNJ to outperform SPY.